Eli Lilly's $3.8 billion psychedelic deal forces a sector-wide repricing
After years at the speculative edge of drug development, psychedelic medicine has its first large-cap anchor. Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion, a deal that establishes a valuation reference point…